X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/medivir-presents-data-on-additive-activity-of-fostrox-in-combination-with-lenvima-or-sorafenib-in-non-clinical-tumor-models-at-ilca-301920306.html
https://www.ema.europa.eu/en/documents/overview/sorafenib-accord-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209050
https://www.prnewswire.com/news-releases/camrelizumab-in-combination-with-rivoceranib-apatinib-significantly-prolonged-overall-survival-and-progression-free-survival-vs-sorafenib-in-patients-with-unresectable-hepatocellular-carcinoma-in-a-multinational-phase-3-trial--301621486.html
https://www.biospace.com/article/releases/dr-reddy-s-laboratories-announces-the-launch-of-the-generic-version-of-nexavar-sorafenib-tablets-usp-200-mg-in-the-u-s-market/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216073
https://endpts.com/after-18-years-in-development-astrazenecas-ctla-4-antibody-gets-the-red-carpet-treatment-at-the-fda/
https://www.pharmatimes.com/news/innovative_phase_2_trial_targets_advanced_liver_cancer_1386784
https://www.fiercepharma.com/marketing/merck-grabs-lifeline-for-problematic-keytruda-liver-cancer-nod-thanks-to-asian-trial-win
https://www.evaluate.com/vantage/articles/news/snippets/keytrudas-liver-success-again-raises-asia-question
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209567
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207012
https://www.businesswire.com/news/home/20200303005066/en/MiNA-Therapeutics-Announces-Initiation-Phase-Clinical-Study
https://pharmaphorum.com/news/onquality-pharma-raises-15m-for-drug-to-treat-vegf-side-effects/
https://endpts.com/bristol-myers-squibbs-opdivo-couldnt-topple-nexavar-in-hcc-but-will-better-safety-profile-win-over-physicians/
https://www.biospace.com/article/with-additional-os-data-in-hand-aveo-oncology-eyes-nda-for-rcc-drug-tivozanib/?s=95
https://www.biopharmadive.com/news/meet-the-protein-responsible-for-nearly-100b-in-cancer-drug-deals/561097/
http://www.pharmafile.com/news/525968/transgene-terminates-oncolytic-io-combo-trial-advanced-liver-cancer
https://www.biospectrumasia.com/news/39/14156/sillajen-to-discontinue-phocus-trial-for-advanced-liver-cancer.html
https://www.fiercebiotech.com/biotech/phase-3-trial-transgene-s-oncolytic-virus-halted-for-futility
https://endpts.com/korean-biotech-sees-shares-blitzed-as-its-oncolytic-virus-nexavar-combo-fizzles-in-liver-cancer/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209050
https://www.fiercepharma.com/pharma/bristol-myers-opdivo-fails-to-beat-nexavar-earlier-use-liver-cancer
https://www.fiercepharma.com/pharma/can-stivarga-crack-code-bayer-hunts-for-rare-glioblastoma-nod-big-5-contender
https://www.medpagetoday.com/hematologyoncology/chemotherapy/78973?xid=nl_mpt_DHE_2019-04-03&eun=g967305d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202019-04-03&utm_term=NL_Daily_DHE_Active
https://endpts.com/israeli-biotech-flunks-phii-liver-cancer-study-but-it-insists-drug-can-fite-disease-in-subset-of-patients/
http://www.pharmatimes.com/news/stivarga_final_nice_recommendation_for_hepatocellular_carcinoma_1274383
http://www.pharmafile.com/news/519695/nice-recommends-lenvima-alternative-first-line-therapy-advanced-liver-cancer
https://www.businesswire.com/news/home/20181204005977/en/Exelixis-Ipsen-Initiate-Phase-3-Pivotal-Trial/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
http://www.pharmatimes.com/news/msds_keytruda_approved_for_liver_cancer_1259747
http://www.pharmatimes.com/news/msds_keytruda_approved_for_liver_cancer_1259747
http://www.pharmatimes.com/news/lenvima_backed_for_nhs_use_to_treat_liver_cancer_1259414
http://www.pharmatimes.com/news/lenvima_backed_for_nhs_use_to_treat_liver_cancer_1259414
https://www.fiercebiotech.com/biotech/novartis-farms-out-rare-disease-drug-to-lifemax-labs
http://www.pharmatimes.com/news/lenvima_wins_green_light_in_liver_cancer_1249253
https://www.rdmag.com/news/2018/08/scientists-develop-novel-drug-could-potentially-treat-liver-cancer-more-effectively
https://www.businesswire.com/news/home/20180702005387/en/Drugs-Mechanism-Action-Utilized-Namodenoson-Recommended-Leading
http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2018-02-23-three-thyroid-cancer-drugs-approved-for-nhs-in-england
http://www.fiercepharma.com/pharma/nice-shoots-down-bayer-s-stivarga-liver-cancer-citing-price-clinical-questions
Market Place
Share 
